| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/03/2023 | 196% | HC Wainwright & Co. | → $37 | Reiterates | → Buy |
| 03/28/2023 | 220% | Oppenheimer | $36 → $40 | Maintains | Outperform |
| 03/27/2023 | 196% | HC Wainwright & Co. | → $37 | Reiterates | → Buy |
| 02/22/2023 | 196% | HC Wainwright & Co. | → $37 | Reiterates | → Buy |
| 02/16/2023 | 196% | HC Wainwright & Co. | → $37 | Reiterates | → Buy |
What is the target price for Pharming (PHAR)?
The latest price target for Pharming (NASDAQ: PHAR) was reported by HC Wainwright & Co. on August 3, 2023. The analyst firm set a price target for $37.00 expecting PHAR to rise to within 12 months (a possible 196.00% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pharming (PHAR)?
The latest analyst rating for Pharming (NASDAQ: PHAR) was provided by HC Wainwright & Co., and Pharming reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Pharming (PHAR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pharming, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pharming was filed on August 3, 2023 so you should expect the next rating to be made available sometime around August 3, 2024.
Is the Analyst Rating Pharming (PHAR) correct?
While ratings are subjective and will change, the latest Pharming (PHAR) rating was a reiterated with a price target of $0.00 to $37.00. The current price Pharming (PHAR) is trading at is $12.50, which is within the analyst's predicted range.